Definium Therapeutics Announces Positive Phase 3 Topline Data for DT120 ODT

What Happened
Definium Therapeutics, Inc. (DFTX) announced on August 12, 2026 that it has reported positive topline results from its Phase 3 Voyage study of DT120 ODT for the treatment of generalized anxiety disorder. The company made the disclosure via a press release and posted a presentation on its website; both documents were included as exhibits to the Form 8-K (Items 7.01 and 8.01).

Key Details

• Announcement date: August 12, 2026 (Form 8-K filing).
• Product/study: DT120 ODT; Phase 3 Voyage study for generalized anxiety disorder.
• Materials provided: Press release (Exhibit 99.1) and topline data presentation (Exhibit 99.2) posted to the company website.
• SEC items: Regulation FD disclosure (Item 7.01) and Other Events (Item 8.01) reported in the 8-K.

Why It Matters
A positive Phase 3 topline readout is a major clinical milestone for a development-stage drug and is typically material to investors because it reflects the company’s progress in advancing its pipeline. The filing shows Definium is publicly releasing topline results and investor materials, which may affect upcoming clinical, regulatory, and commercial expectations—investors should review the attached press release and presentation for detailed data and any next-step guidance from the company.